225 Actinium PSMA 617 - Endocyte

Drug Profile

225 Actinium PSMA 617 - Endocyte

Alternative Names: 225 Actinium PSMA 617; 225Ac PSMA 617

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endocyte
  • Developer Endocyte; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 02 Nov 2017 Preclinical trials in Prostate cancer (Metastatic disease) in USA (Parenteral)
  • 02 Nov 2017 Endocyte, in collaboration with the Memorial Sloan Kettering Cancer Center plans a phase I trial of 225Ac-PSMA-617, in 1H 2018, for the treatment of patients with metastatic castration-resistant prostate cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top